Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186201 | 0.91 | DGAT1 (0.46) | DGAT1MAOAMAOB | |
| SCHEMBL27771798 | 0.80 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL27635112 | 0.73 | DGAT1 (0.60) | DGAT1CA12CA14MAOAMAOB | |
| SCHEMBL27635111 | 0.73 | DGAT1 (0.60) | DGAT1CA12CA14MAOAMAOB | |
| SCHEMBL1731211 | 0.73 | DGAT1 (0.60) | DGAT1CA12CA14MAOAMAOB | |
| SCHEMBL9248229 | 0.73 | DGAT1 (0.60) | DGAT1CA12CA14CA2 | |
| SCHEMBL1735445 | 0.72 | DGAT1 (1.00) | DGAT1CA12CA14CA2 | |
| SCHEMBL9784263 | 0.72 | DGAT1 (0.58) | DGAT1MAOAMAOB | |
| SCHEMBL28714854 | 0.70 | DGAT1 (0.44) | DGAT1MAOAMAOB | |
| SCHEMBL29908023 | 0.70 | DGAT1 (0.44) | DGAT1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101484171-B | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES INC | 2015-05-06 | — | — | CN | disclosed |
| US-8580746-B2 | Amide linkage cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580747-B2 | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| CN-101505784-B | Cyclic natriuretic peptide constructs | PALATIN TECHNOLOGIES INC | 2013-08-21 | — | — | CN | disclosed |
| EP-2001518-B1 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8114844-B2 | Linear and cyclic melanocortin receptor-specific peptidomimetics | PALATIN TECHNOLOGIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | PALATIN TECHNOLOGIES, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7964181-B2 | Amino acid surrogates for peptidic constructs | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7795221-B2 | Linear natriuretic peptide constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2004633-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2004352-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| EP-2001518-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | Palatin Technologies, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007115164-A9 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES INC (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007115164-A2 | AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115175-A2 | CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007115182-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263818-A1 | Peptidic Constructs with Amino Acid Surrogates | ARGLU1, QRFPR, ARG1 | DGAT1 4730/4885CA12 2592/4885CA14 3264/4885 |
| US-20070265206-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | DGAT1 4797/4885CA12 2302/4885CA14 2679/4885 |
| US-20070260040-A1 | Amino Acid Surrogates for Peptidic Constructs | ARGLU1, ARG1, QRFPR | DGAT1 4761/4885CA12 1897/4885CA14 2581/4885 |
| US-20070232546-A1 | Linear Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | DGAT1 4816/4885CA12 2239/4885CA14 2608/4885 |
| US-20100075895-A1 | Cyclic Natriuretic Peptide Constructs | NPR1, NPR3, NPPA | DGAT1 4797/4885CA12 2302/4885CA14 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.